Today we announced a landmark partnership with Eli Lilly and Company to use our AI models to design recombinases for genetic medicine—a collaboration valued at up to $2.25 billion before royalties.The goal: use Profluent's AI models to design recombinase editors capable of inserting long stretches of DNA at precise locations in the genome.Many genetic diseases involve hundreds of different mutations across patients–no single edit can address them all. Inserting a complete functional gene with a ...

Profluent

We're partnering with Eli Lilly and Company to use our AI models to design recombinase proteins for gene editing—a collaboration valued at up to $2.25 billion.Read the Bloomberg story: https://lnkd.in/eef5e2NXAnd read our press release for more: https://lnkd.in/e5_NQUw8 ...

Profluent